glp 1 euglycemic dka Diabetic Ketoacidosis: Clinical Suspicion and Diagnosis Why GLP-1 Agonists May Not

The FDA has urged patients not to take these compounded drugs because they are not safe for weight loss or any other use of Ozempic

Morton points to retatrutide, a weekly injection from Eli Lilly currently in clinical development for obesity and type 2 diabetes, as an example

Heres why, as well as who may benefit most from microdosing and what to know before trying it

Roy Cooper

MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in People Living With Obesity or Overweight MariTide is the First Obesity Treatment With Monthly or Less Frequent Dosing to Demonstrate Safe and Effective Weight Loss in a Phase 2 Study In People With Type 2 Diabetes Living With Obesity or Overweight MariTide Demonstrated up to ~17% Average Weight Loss Without a Weight Loss Plateau and Lowered Average HbA1c by up to 2

Glucagon-like peptide 1 receptor agonists and heart failure: The need for further evidence generation and practice guidelines optimization